The US District Court for the District of New Jersey has issued a favourable ruling in the Teva Pharmaceutical Industries' patent infringement lawsuit against Mylan regarding an Azilect (rasagiline tablets) patent which covers methods of treating Parkinson’s disease (PD). The Court has upheld the validity of Teva’s patent. Teva anticipates the Court will enter Judgment that prevents Mylan from launching its generic version of Azilect until Teva’s patent expires in 2017.

Teva filed a lawsuit suit against Mylan in October 2010. Similar lawsuits were filed against Watson and Orchid in October 2010, Apotex in May 2011 and Sandoz in April 2012. Teva reached settlement agreements with Watson, Apotex and Orchid earlier this year. Sandoz has agreed to be bound by a final judgment in the case against Mylan.

Teva is pleased with the ruling, which further confirms the strength of Teva’s Azilect intellectual property rights. Azilect has an established efficacy, safety and tolerability profile in PD patients since its launch in 2006 and Teva is confident it is well positioned in the marketplace.

Teva will continue to support the scientific community by further investigating the clinical profile of Azilect and offering important resources, education and financial assistance to patients and physicians through the Parkinson’s Support Solutions programme.

Azilect (rasagiline tablets) is indicated for the treatment of the signs and symptoms of Parkinson’s disease (PD) both as initial therapy alone and to be added to levodopa later in the disease.